ATEC Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $214 million, up 15% year-over-year, with surgical revenue at $196 million (up 17%).
Adjusted EBITDA: $36 million, a 53% increase year-over-year, with a margin of 17%.
Gross Margin: 72.5%, improved by 260 basis points year-over-year.
Cash Flow: Generated $34 million in operating cash flow, with positive free cash flow of approximately $1 million.
Liquidity: Ended the quarter with $119 million in cash and $85 million in available borrowing capacity.

2. Strategic Updates and Business Highlights

Surgeon Adoption: New surgeon users increased by 24%, with procedural volume growth at 20%, indicating strong market momentum.
EOS Revenue: $17 million, reflecting stable demand and the strategic importance of EOS Insight in driving procedural adoption.
Product Development: Continued focus on integrating products into comprehensive procedures rather than standalone items, enhancing surgeon confidence and adoption.
International Growth: Successful expansion into markets like Japan, Australia, and New Zealand, replicating the company's clinical distinction model.

3. Forward Guidance and Outlook

Revenue Guidance: Maintaining full-year revenue guidance of approximately $882 million (15% growth), with surgical revenue expected to be around $805 million (17% growth).
Adjusted EBITDA Guidance: Raised to approximately $140 million (16% margin), up from a previous estimate of $134 million.
Free Cash Flow: Expecting $4 million to $6 million in Q3, with a full-year target of at least $20 million.

4. Challenges and Points of Concern

Biologics Attachment Rate: Stabilized but remains below prior year levels, impacting revenue per case, which is expected to decline in the low single digits for the year.
Revenue Per Case: Average revenue per case declined approximately 2.7% year-over-year, attributed to case mix and international growth dynamics.
Market Dynamics: Some concerns about potential procedure volume slowdowns in the broader orthopedic market, although ATEC has not experienced significant impacts.

5. Notable Q&A Insights

Surgeon Growth Opportunities: CEO Pat Miles highlighted significant potential in lateral procedures and biologics attachment as areas for future growth.
EOS Insight Penetration: Currently at 15-20% penetration among EOS installations, with expectations for rapid adoption as surgeons recognize its value.
Surgical Trends: Confidence in maintaining high surgical volume growth, driven by new product acceptance and ongoing surgeon engagement.
Competitive Landscape: ATEC's focus on creating clinical distinction and improving surgical outcomes is seen as a key differentiator in the competitive spine surgery market.

Overall, ATEC reported a strong quarter with solid growth metrics, a positive outlook for the remainder of the year, and strategic initiatives aimed at enhancing surgeon adoption and procedural integration. However, challenges remain in biologics attachment and revenue per case, which the company is actively addressing.

ATEC — Alphatec Holdings, Inc.